D’expert « anti-vax »

Je ne trouve pas idéologie dans la pyramide du niveau de preuve. Et vous?

Site-specific complications of central venous catheterization under systematic ultrasound guidance: a target trial emulation revisiting the 3SITES study - Critical Care Background Central venous catheterization is the most common invasive procedure in intensive care units but remains burdened by infectious, thrombotic, and mechanical complications. Although real-time...

Does subclavian CVC still carry higher pneumothorax risk in the ultrasound era? 🫁

New emulated reanalysis of the 3SITES RCT shows:

❌ Subclavian excess PNO risk DISAPPEARS with ultrasound

✅ LOWER CRBSI w subclavian vs jugular/femoral

link.springer.com/article/10.1...

Proud to hit 100 peer-reviews for @TheLancetHIV! 🎉

As a stats reviewer, here are 3 red flags 🛑😒that yields to reject⛔️:

1️⃣ Cc driven by hypothesis, not data 🙄
2️⃣ Primary outcome swap for p-value 🕵🏻‍♂️
3️⃣ Stats copy-pasted 🤡 by ppl who don’t understands it
#HIV #peerRW

My birth date (DD/MM/YY) is not just a #palindrome
It combines the #worst and the #best hand in #poker
27 - AA - 72 !
😅😉

Cluster of 3 lampshades
Colors are not random
Do you like the intra-class correlation?
#Handmade in 🇫🇷

Volume 81 Issue Supplement_2 | Clinical Infectious Diseases | Oxford Academic An official journal of the Infectious Diseases Society of America. Publishes on clinical descriptions of infections, public health, microbiology, and immunology; infection prevention; treatment evalua...

In the context of vaccine hesitancy😱, this outstanding research🤩highlights decades of dedicated efforts to develop safe and effective vaccines💉. 🛟🛟🛟

Smallpox eradication to modern innovations,
👀 history and rigorous processes behind these life-saving tools.

FREE!

academic.oup.com/cid/issue/81...

Masterclass présentation by Prof. Anne-Genevieve Marcelin on new ART @eacsociety.bsky.social #EACS2025Paris
NO SEAT AVAILABLE!
#IDSky #HIVSky

Trop de haine pour que ça tienne

Let’s go dismantle the methodological puzzle of the link btw InSTI and cardiometabolic risk among #PWH at #SynergieResistance #Aix_en_provence

The thème is Gardian of the Galaxy!
#RESPOND #SwissCohort #HIV_Causal

Exactement! Lamelles = danger pour le néophyte

En évitant ceux à lamelles, ça réduit fortement le risque…
Il reste bolets et cèpes !

Table 2. Incidence of RSV-Associated Secondary End Points in RSV Season 1.

RSV remains a severe infection in infants and children. In this report, data on the activity of clesrovimab, a long-lasting RSV monoclonal antibody, are described as compared with palivizumab. Full interim results for the SMART phase 3 trial: nej.md/4poVkDE

#MedSky #IDSky #PedSky

This challenge could be repeated 😂
based on mood or surroundings

Rock b6, then Q takes K

Sometimes correlation does not mean causation
Sometimes outlier does not improve precision

Sometimes it does.

Lovely!

Racoon in French is **raton laveur**

*Laveur* means "washer" from the observed behavior of raccoons, which often handle their food near water, giving the impression that they are "washing" it

Always a pleasure to help the french speaking community

Just tag my name and SuperStat JJ 🦸‍♂️ will be there from 🇫🇷 for R💙R💜
😊

Looks like ppl on IV Tx were more severe?

CID: Background HIV Incidence in PURPOSE 1 and 2 PrEP trials
Jean-Jacques Parienti

HIV incidence among low-adherence oral PrEP users in PURPOSE 1 and 2 closely matched or slightly exceeded background HIV incidence

bit.ly/4ltz5JO

But I agree w you it is not straightforward when you do not practice stat methodology daily.

Because it is around 50% (👀 @ the 95% CI rather than point estimate) this result is perfectly consistant with the similar clinical success (i.e. NI for secondary endpoint).

W Dalba, you avoid central venous access, as u said« which are not risk-free spigot » (quote from my mentor Len Mermel!)

Oh, wow!

The vaccine to this wrong belief is:

Au are talking about the probability for Dalba to be superior to SOC on the DOOR outcome.

Making Sense of Hierarchical Composite End Points in Randomized Clinical Trials—A Primer for Infectious Diseases Clinicians and Researchers Hierarchical composite end points (HCEs) are increasingly being used in infectious diseases research. In this review aimed at educating the clinical reader

Here a paper w nice illustrations academic.oup.com/cid/advance-...

As a poker player, I am well trained to the prob of having the best hand.
Hands w <50% is not good in heads-up @paulsaxmd.bsky.social
Think of the discrimination index for a diagnostic test. The cut-off for the area under the ROC curve to be useful is 50%

Yes.

But the authors also provided efficacy results (secondary outcome) in a more traditional way, i.e. Risk Difference and 95% CI btw the 2 randomized arms, and had computed a NI margin a priori, Albert underpowered😉

It seems they have done all this for ppl who like to keep the door closed

This is was I did & bHIV underestimated the risk of HIV (conservative)
😉👏👍

Background HIV Incidence in PURPOSE 1 and 2 PrEP trials Abstract. HIV incidence among low-adherence oral PrEP users in PURPOSE 1 and 2 closely matched or slightly exceeded background HIV incidence (bHIV), suppor

What if comparing :
🔵 background #HIV incidence (MODEL)

to

🔴 HIV incidence (REAL) among ppl w low-level adherence to oral #PrEP (<2💊/wk by DBS- unprotected)

in PURPOSE trials?
👇🏾👇🏽👇🏻👇
academic.oup.com/cid/advance-...

🇫🇷 I generally reply in french question asked in french

♟️Like in chess openings, the back defense is driven by the white first moves? 😉😉

Ty for nice words😊

Pas besoin d’être PhD en stat pour penser que c’est probablement pas très différent !